Jefferies, Deutsche Bank are bookrunners; greenshoe for $11.54 million
By Devika Patel
Knoxville, Tenn., Jan. 19 - Neurocrine Biosciences, Inc. priced a $76.95 million public sale of stock with an $11.54 million greenshoe in a prospectus supplement filed Thursday with the Securities and Exchange Commission. The deal was announced Wednesday.
The company will sell 9.5 million common shares at $8.10 apiece. The price per share is a 6.25% discount to the Jan. 18 closing share price of $8.64.
Jefferies & Co., Inc. and Deutsche Bank Securities Inc. are the joint bookrunning managers. Piper Jaffray & Co. and Leerink Swann LLC are the co-managers.
Settlement is expected Jan. 24.
Proceeds will be used for research and development efforts and general corporate purposes, including working capital.
Neurocrine is a San Diego-based product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders.
| Issuer: | Neurocrine Biosciences, Inc.
|
| Issue: | Common shares
|
| Amount: | $76.95 million
|
| Greenshoe: | $11,542,500
|
| Shares: | 9.5 million
|
| Price: | $8.10
|
| Warrants: | No
|
| Bookrunners: | Jefferies & Co., Inc. and Deutsche Bank Securities Inc.
|
| Co-managers: | Piper Jaffray & Co. and Leerink Swann LLC
|
| Announcement date: | Jan. 18
|
| Pricing date: | Jan. 19
|
| Settlement date: | Jan. 24
|
| Stock symbol: | Nasdaq: NBIX
|
| Stock price: | $8.64 at close Jan. 18
|
| Market capitalization: | $448.13 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
